Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | In stock | $ 954.00 | |
50 mg | In stock | $ 1,240.00 | |
100 mg | In stock | $ 1,990.00 |
Description | SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor. |
In vitro | The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells), and MDA-MB-231 (breast carcinoma cells). For inhibition of growth of A431, MIA PaCa-2, and MDA-MB-231 cells the IC50 values are 0.21 μM, 0.29 μM, and 0.43 μM, respectively [1]. |
In vivo | Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. SDZ 281-977 (30 mg/kg, p.o.) treatment causes a 54% inhibition of A431 tumor growth after 3 weeks of treatment [1]. |
Synonyms | SDZ-LAP 977 |
Molecular Weight | 316.35 |
Formula | C18H20O5 |
CAS No. | 150779-71-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SDZ281-977 150779-71-8 Others SDZ281 977 SDZ-281-977 SDZ281977 SDZ-LAP 977 SDZ-LAP-977 SDZ-LAP977 inhibitor inhibit